Literature DB >> 8505104

Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade.

B Jover1, A Herizi, F Ventre, M Dupont, A Mimran.   

Abstract

The influence of dietary sodium restriction and angiotensin II blockade on hypertension induced by a 25-day period of administration of the inhibitor of nitric oxide synthesis NG-nitro-L-arginine-methyl ester (10 mg/kg twice daily by gavage) was assessed in Wistar rats fed a normal or low sodium diet. In addition, the angiotensin II receptor blocker losartan (30 mg/kg once daily by gavage) was administered before and during NG-nitro-L-arginine-methyl ester in rats fed the normal sodium diet. At the end of the studies, conscious systolic arterial pressure increased similarly in NG-nitro-L-arginine-methyl ester-treated groups maintained on normal or low sodium intake. Moreover, a 25% reduction in cardiac output due to a decrease in stroke volume was observed in both groups. A slight but significant cardiac hypertrophic response was observed in hypertensive rats irrespective of sodium intake. At the completion of studies, plasma renin activity was similar to corresponding controls in the hypertensive groups on normal or low sodium intake. Losartan totally prevented the development of hypertension as well as the decrease in stroke volume and cardiac hypertrophy associated with NG-nitro-L-arginine-methyl ester treatment in rats on normal sodium intake. In conclusion, hypertension resulting from long-term blockade of nitric oxide synthesis was not affected by dietary sodium restriction. A crucial role for the renin-angiotensin system was demonstrated in this new model of hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505104     DOI: 10.1161/01.hyp.21.6.944

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  Antihypertensive and antioxidant potential of vanillic acid, a phenolic compound in L-NAME-induced hypertensive rats: a dose-dependence study.

Authors:  Subramanian Kumar; Pichavaram Prahalathan; Boobalan Raja
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

Review 2.  Chronic nitric oxide inhibition model six years on.

Authors:  R Zatz; C Baylis
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

3.  Pentaerythrityl tetranitrate attenuates structural changes in conduit arteries evoked by long-term NO-synthase inhibition.

Authors:  F Kristek
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar rats.

Authors:  F J Dowell; D Henrion; M Duriez; J B Michel
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

5.  Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase.

Authors:  A Ollerstam; J Pittner; A E Persson; C Thorup
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model.

Authors:  P Soares-da-Silva; M Pestana; M A Vieira-Coelho; M H Fernandes; A Albino-Teixeira
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease.

Authors:  H Moreno; K Metze; A C Bento; E Antunes; R Zatz; G de Nucci
Journal:  Basic Res Cardiol       Date:  1996 May-Jun       Impact factor: 17.165

8.  Role of cGMP-kinase II in the control of renin secretion and renin expression.

Authors:  C Wagner; A Pfeifer; P Ruth; F Hofmann; A Kurtz
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME.

Authors:  Zuzana Honetschlägerová; Kento Kitada; Zuzana Husková; Alexandra Sporková; Libor Kopkan; Marcela Bürgelová; Šárka Varcabová; Akira Nishiyama; Sung Hee Hwang; Bruce D Hammock; John D Imig; Herbert J Kramer; Petr Kujal; Zdenka Vernerová; Luděk Červenka
Journal:  J Hypertens       Date:  2013-02       Impact factor: 4.844

10.  Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles.

Authors:  Silvia Elaine Ferreira-Melo; Caroline Demacq; Silvia Lacchini; José Eduardo Krieger; Maria Cláudia Irigoyen; Heitor Moreno
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.